NCT05948813View on ClinicalTrials.gov

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2027

Conditions
NSCLCEGFR Activating MutationBrain Metastases
Interventions
DRUG

TY-9591

The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.

DRUG

Osimertinib

The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

TYK Medicines, Inc

INDUSTRY